Onodera
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Japanese gene therapy biotech developing AAV-based treatments for neurodegenerative diseases like ALS and Parkinson's.
NeurologyRare Disease
Technology Platform
Adeno-associated virus (AAV) vector-based gene delivery platform for targeting central nervous system (CNS) diseases and monogenic disorders.
Opportunities
Opportunities include leveraging Japan's strong academic research network to source new programs, and capitalizing on strategic manufacturing and funding alliances to accelerate lead CNS gene therapies into clinical trials.
Risk Factors
Key risks include the high scientific and clinical hurdles of developing effective gene therapies for complex neurodegenerative diseases like sporadic ALS, and reliance on a narrow pipeline and key personnel.
Competitive Landscape
Competes with global gene therapy biotechs (e.g., UniQure, Voyager Therapeutics) in neurodegenerative diseases, but differentiates through its position as a domestic Japanese AAV research hub and academic collaboration network.